Preoperative Endoscopic Retrograde Cholangiopancreatography Is Not Associated With Increased Pancreatic Cancer Mortality Sheila D. Rustgi, Sunil Amin, Anthony Yang, Michelle K. Kim, Satish Nagula, Nikhil A. Kumta, Christopher J. DiMaio, Paolo Boffetta, Aimee L. Lucas Clinical Gastroenterology and Hepatology Volume 17, Issue 8, Pages 1580-1586.e4 (July 2019) DOI: 10.1016/j.cgh.2018.11.056 Copyright © 2019 AGA Institute Terms and Conditions
Figure 1 Patient cohort selection. ERCP, endoscopic retrograde cholangiopancreatography; ICD-O-2, International Classification of Diseases for Oncology, 2nd ed; PDAC, pancreatic ductal adenocarcinoma. Clinical Gastroenterology and Hepatology 2019 17, 1580-1586.e4DOI: (10.1016/j.cgh.2018.11.056) Copyright © 2019 AGA Institute Terms and Conditions
Figure 2 Kaplan–Meier curve of patients receiving preoperative ERCP vs no preoperative ERCP. Survival was 18.8 months for those who underwent preoperative ERCP compared with 18.5 months for those who did not receive preoperative ERCP (P = .22). ERCP, endoscopic retrograde cholangiopancreatography. Clinical Gastroenterology and Hepatology 2019 17, 1580-1586.e4DOI: (10.1016/j.cgh.2018.11.056) Copyright © 2019 AGA Institute Terms and Conditions